Beyond AWP . . . Way Beyond (Englisch)
- Neue Suche nach: Willke, R. J.
- Neue Suche nach: Willke, R. J.
In:
VALUE IN HEALTH
;
13
, 1
;
1-1
;
2010
-
ISSN:
- Aufsatz (Zeitschrift) / Print
-
Titel:Beyond AWP . . . Way Beyond
-
Beteiligte:Willke, R. J. ( Autor:in )
-
Erschienen in:VALUE IN HEALTH ; 13, 1 ; 1-1
-
Verlag:
- Neue Suche nach: Blackwell Publishing Ltd
-
Erscheinungsdatum:01.01.2010
-
Format / Umfang:1 pages
-
ISSN:
-
Medientyp:Aufsatz (Zeitschrift)
-
Format:Print
-
Sprache:Englisch
- Neue Suche nach: 610
- Weitere Informationen zu Dewey Decimal Classification
-
Klassifikation:
DDC: 610 -
Datenquelle:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Inhaltsverzeichnis – Band 13, Ausgabe 1
Zeige alle Jahrgänge und Ausgaben
Die Inhaltsverzeichnisse werden automatisch erzeugt und basieren auf den im Index des TIB-Portals verfügbaren Einzelnachweisen der enthaltenen Beiträge. Die Anzeige der Inhaltsverzeichnisse kann daher unvollständig oder lückenhaft sein.
- 1
-
Beyond AWP . . . Way BeyondWillke, R. J. et al. | 2010
- 2
-
What's in a Perspective?Glick, H. A. et al. | 2010
- 3
-
Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations: The ISPOR Drug Cost Task Force Report-Part IHay, J. W. / Smeeding, J. / Carroll, N. V. / Drummond, M. / Garrison, L. P. / Mansley, E. C. / Mullins, C. D. / Mycka, J. M. / Seal, B. / Shi, L. et al. | 2010
- 8
-
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Societal Perspective: The ISPOR Drug Cost Task Force Report-Part IIGarrison, L. P. / Mansley, E. C. / Abbott, T. A. / Bresnahan, B. W. / Hay, J. W. / Smeeding, J. et al. | 2010
- 14
-
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Managed Care Perspective: The ISPOR Drug Cost Task Force Report-Part IIIMansley, E. C. / Carroll, N. V. / Chen, K. S. / Shah, N. D. / Piech, C. T. / Hay, J. W. / Smeeding, J. et al. | 2010
- 18
-
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: Medicare, Medicaid and Other US Government Payers Perspectives: The ISPOR Drug Cost Task Force Report-Part IVMullins, C. D. / Seal, B. / Seoane-Vazquez, E. / Sankaranarayanan, J. / Asche, C. V. / Jayadevappa, R. / Lee, W. C. / Romanus, D. K. / Wang, J. / Hay, J. W. et al. | 2010
- 25
-
Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: An Industry Perspective: The ISPOR Drug Cost Task Force Report-Part VMycka, J. M. / Dellamano, R. / Kolassa, E. M. / Wonder, M. / Ghosh, S. / Hay, J. W. / Smeeding, J. et al. | 2010
- 28
-
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: An International Perspective: The ISPOR Drug Cost Task Force Report-Part VIShi, L. / Hodges, M. / Drummond, M. / Ahn, J. / Li, S. C. / Hu, S. / Augustovski, F. / Hay, J. W. / Smeeding, J. et al. | 2010
- 34
-
The Multinational Nature of Cost-Effectiveness Analyses Alongside Multinational Clinical TrialsRivero-Arias, O. / Gray, A. et al. | 2010
- 42
-
Cost-Benefit Analysis of Preventing Nosocomial Bloodstream Infections among Hemodialysis Patients in Canada in 2004Hong, Z. / Wu, J. / Tisdell, C. / O'Leary, C. / Gomes, J. / Wen, S. W. / Njoo, H. et al. | 2010
- 46
-
The Impact of Fewer Hip Fractures with Risedronate Versus Alendronate in the First Year of Treatment: Modeled German Cost-Effectiveness AnalysisThompson, M. / Pasquale, M. / Grima, D. / Moehrke, W. / Kruse, H. P. et al. | 2010
- 55
-
Cost-Effectiveness of Sorafenib for Second-Line Treatment of Advanced Renal Cell CarcinomaHoyle, M. / Green, C. / Thompson-Coon, J. / Liu, Z. / Welch, K. / Moxham, T. / Stein, K. et al. | 2010
- 61
-
Cost-Effectiveness of Temsirolimus for First Line Treatment of Advanced Renal Cell CarcinomaHoyle, M. / Green, C. / Thompson-Coon, J. / Liu, Z. / Welch, K. / Moxham, T. / Stein, K. et al. | 2010
- 69
-
Budget Impact Analysis of Thrombolysis for Stroke in Spain: A Discrete Event Simulation ModelMar, J. / Arrospide, A. / Comas, M. et al. | 2010
- 77
-
Prevalence of Respiratory Syncytial Virus (RSV) Risk Factors and Cost Implications of Immunoprophylaxis to Infants 32 to 35 Weeks Gestation for Health Plans in the United StatesKrilov, L. R. / Palazzi, D. L. / Fernandes, A. W. / Klein, R. W. / Mahadevia, P. J. et al. | 2010
- 87
-
Relationship between Adherence Level to Statins, Clinical Issues and Health-Care Costs in Real-Life Clinical SettingDragomir, A. / Cote, R. / White, M. / Lalonde, L. / Blais, L. / Berard, A. / Perreault, S. et al. | 2010
- 95
-
Relationship between Health-Related Quality of Life, Pain, and Functional Disability in Neuropathic Pain Patients with Failed Back Surgery SyndromeManca, A. / Eldabe, S. / Buchser, E. / Kumar, K. / Taylor, R. S. et al. | 2010
- 103
-
A Multinational Study of Health State Preference Values Associated with Chronic Myelogenous LeukemiaSzabo, S. M. / Levy, A. R. / Davis, C. / Holyoake, T. L. / Cortes, J. et al. | 2010
- 112
-
Patient Characteristics Impacting Health State Index Scores, Measured by the EQ-5D of Females with Stress Urinary Incontinence SymptomsTincello, D. / Sculpher, M. / Tunn, R. / Quail, D. / van der Vaart, H. / Falconer, C. / Manning, M. / Timlin, L. et al. | 2010
- 119
-
Psychometric Development of the Individualized Retinopathy-Dependent Quality of Life Questionnaire (RetDQoL)Brose, L. S. / Bradley, C. et al. | 2010
- 128
-
A Methodology for Successfully Producing Global Translations of Patient Reported Outcome Measures for Use in Multiple CountriesTwo, R. / Verjee-Lorenz, A. / Clayson, D. / Dalal, M. / Grotzinger, K. / Younossi, Z. M. et al. | 2010
- 132
-
Instrumental Variables in Influenza Vaccination Studies: Mission Impossible?!Groenwold, R. H. / Hak, E. / Klungel, O. H. / Hoes, A. W. et al. | 2010
- 138
-
Relationships among Self-Management, Patient Perceptions of Care, and Health Economic Outcomes for Decision-Making and Clinical Practice in Type 2 DiabetesCobden, D. S. / Niessen, L. W. / Barr, C. E. / Rutten, F. F. / Redekop, W. K. et al. | 2010
- 148
-
The Impact of Pharmaceutical Cost Containment Policies on the Range of Medicines Available and Subsidized in Finland and New ZealandAaltonen, K. / Ragupathy, R. / Tordoff, J. / Reith, D. / Norris, P. et al. | 2010
- 157
-
Calibration of Disease Simulation Model Using an Engineering ApproachVanni, T. / Legood, R. / White, R. G. et al. | 2010
- 158
-
Erratum| 2010
- viii
-
ISPOR CODE OF ETHICS:MARCH 2008| 2010